Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Oklo Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Oklo Inc trades at $28.4 (market cap $5.91B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Oklo Inc for 33 Days on average.
| KYMR | OKLO | |
|---|---|---|
Market Cap | $8.87B | $5.91B |
Volume | 779,107 | 8,898,651 |
Sector | Health | Utilities |
52-Week High | $127.31 | $171.56 |
52-Week Low | $55.80 | $29.04 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $8.26B | $3.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKLO trades at $31.78, down 1.33% on the day, with a bearish technical signal despite oversold RSI readings. The company shows no revenue in 2025 and a net loss of $105.66 million, with negative profit margins and ROE. Recent news highlights competition in the nuclear sector and OKLO's $1 billion stock sale, while analyst consensus remains strongly bullish with a $78.63 price target.
OKLO presents high-risk, high-reward potential as an early-stage nuclear company. The bullish analyst outlook and strategic project pipeline offer upside, but significant execution risks, cash burn, and competitive pressures require careful consideration. Investor sentiment is mixed amid operational challenges and dilution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
